dbco-peg-1

DBCO-PEG1 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG1-acid is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG1-amine is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG1-NH-Boc is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG1-NHS ester is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG10-DBCO is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG12-acid is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG12-NHS ester is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG13-DBCO is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-PEG2-C2-acid作为一种ADC连接子，常用于合成抗体药物偶联物（Antibody-Drug Conjugates (ADCs)）。

Azido-PEG7-amine是一种不可降解(non-cleavable)的ADC linker和PEG类的PROTAC linker，可用于合成抗体偶联分子(ADC)和PROTAC，可以和含有Alkyne、DBCO或BCN基团的分子发生点击化学反应。

DBCO-acid is a cleavable ADC linker utilized in the synthesis of ADC linker DBCO-NHS ester and drug-linker conjugates DBCO-PEG-MMAE[1].

DBCO-NHCO-PEG5-NHS ester is a polyethylene glycol (PEG)-based linker utilized in the synthesis of PROTACs[1].

DBCO-PEG4-NHS ester 是一种属于 PEG 类的 PROTAC linker，可用于 PROTAC 分子的合成。

APN-PEG4-DBCO is a cleavable linker for antibody-drug conjugates (ADCs), comprised of a four-unit PEG and a DBCO moiety. It finds application in the synthesis of ADCs[1].

Carboxyrhodamine 110-PEG4-DBCO is a PEG-based PROTAC linker utilized in PROTAC synthesis[1].

DBCO-C-PEG1 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-NH-PEG7-C2-NHS ester is a polyethylene glycol (PEG) derived linker that possesses a terminal DBCO moiety. It functions as an N-hydroxysuccinimide (NHS) ester, making it suitable for the efficient synthesis of proteolysis-targeting chimeras (PROTACs)[1].

DBCO-NHCO-PEG12-maleimide is a PEG-based PROTAC linker utilized in the synthesis of PROTACs[1].

DBCO-NHCO-PEG2-maleimide is a polyethylene glycol (PEG) derived PROTAC linker utilized during PROTAC synthesis[1].

DBCO-NHCO-PEG2-NHS ester, a PEG-based PROTAC linker, enables the synthesis of PROTACs[1].

DBCO-NHCO-PEG6-maleimide is a polyethylene glycol (PEG)-based linker compound employed in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

DBCO-PEG3-TCO is a non-cleavable three-unit polyethylene glycol (PEG) linker employed for synthesizing antibody-drug conjugates (ADCs)[1].

DBCO-PEG4-alkyne is a four-unit PEG linker with non-cleavable properties, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].